Abstract
Pediatric COVID-19 (pCOVID-19) is rarely severe, however a minority of SARS-CoV-2-infected children may develop MIS-C, a multisystem inflammatory syndrome with significant morbidity. In this longitudinal multi-institutional study, we used multi-omics to identify novel time- and treatment-related immunopathological signatures in children with COVID-19 (n=105) and MIS-C (n=76). pCOVID-19 was characterized by enhanced type I IFN responses, and MIS-C by type II IFN- and NF-κB dependent responses, matrisome activation, and increased levels of Spike protein. Reduced levels of IL-33 in pCOVID-19, and of CCL22 in MIS-C suggested suppression of Th2 responses. Expansion of TRBV11-2 T-cell clonotypes in MIS-C was associated with inflammation and signatures of T-cell activation, and was reversed by glucocorticoids. The association of MIS-C with the combination of HLA A*02, B*35, C*04 alleles suggests genetic susceptibility. MIS-C B cells showed higher mutation load. Use of IVIG was identified as a confounding factor in the interpretation of autoantibody levels.
Competing Interest Statement
TH is an employee and shareholder of CDI Laboratories. MA is a consultant for CDI Laboratories and the owner of Biomedical Hosting, LLC. TMS and IMK declare employment and equity ownership with Adaptive Biotechnologies.
Funding Statement
This work was supported by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases and National Institute of Dental and Craniofacial Research, National Institutes of Health (grant ZIA AI001270-01 to LDN and ZIA AI001265 to HCS), by Regione Lombardia, Italy (project 'Risposta immune in pazienti con COVID-19 e co-morbidita' to RC, AL, DM, GLM for Pavia, Italy and LI and AS for Brescia, Italy), by ANID COVID 0999, Fondecyt no 11181222 (to MCP, Chile). In addition, this project has been funded in part with federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. 75N91019D00024 (to DBK). The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. Moreover, the opinions and assertions expressed herein are those of the authors and are not to be construed as reflecting the views of Uniformed Services University of the Health Sciences or the United States Department of Defense. RC is a participant in the USA National Institutes of Health (NIH) Graduate Partnership Program between NIH and the University of Pavia, Italy. SV is funded by The Finnish Medical Foundation and Orion Research Foundation sr.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Chile IRB: Comite Etico Cientifico Facultad de Medicina Clinica Alemana Universidad del Desarrollo, Santiago, Chile Protocol: 2020-41 Title: Infeccion por Sars CoV-2 y enfermedad Covid-19: caracterizacion epidemiologica, clinica, virologica e inmunologica (SARS-CoV-2 infection and COVID-19: Epidemiologic, clinical, virologic and immunologic characterization) Pavia, Italy IRB: Ethics Committee of the Fondazione IRCCS Policlinico San Matteo, Pavia Protocol: 20200037677 Title: Analisi comprensiva della risposta immunitaria innata ed adattativa durante la fase acuta e la convalescenza in COVID-19 Turin, Italy IRB: Comitato Etico Interaziendale A.O.U. Citta della Salute e della Scienza di Torino Protocol: 00282/2020 Title: Immunofenotipo SCiKH Naples, Italy IRB: Ethics Committee of the University of Naples Federico II Protocol: 158/20 for all COVID-19 patients Title: Analisi comprensiva della risposta immunitaria innata ed adattativa durante la fase acuta e la convalescenza dell infezione da COVID-19 (Comprehensive analysis of the innate and adaptive immune response in acute phase and convalescence of COVID-19 patients) Brescia, Italy IRB: Comitato Etico Provinciale Protocol: NP-4000 Title: Indagini di laboratorio e infezione da COVID19, Studio CORONAlab Monza, Italy IRB: University of Milano Bicocca, San Gerardo Hospital, Monza and Ethics Committee of the National Institute of Infectious Diseases 'Lazzaro Spallanzani' Protocol: 84/2020 Title: Observational cohort study on the natural history of hospitalized SARS-COV-2 patients: the STORM trial. Israel IRB: Hadassah Medical Organization Institutional Review Board (IRB) for studies involving human subjects. Protocol: HMO-235-20 Title: Collection of blood specimens from patients diagnosed with COVID19, SARS-COV-2 carriers and members of their families, for purposes of monitoring biomarkers and their immune response. IRB NIAID-NIH Protocol: 18-I-0041 (NCT03394053) Title: Investigating the Mechanistic Biology of Primary Immunodeficiency Disorders IRB NIAID-NIH Protocol: 18-I-0128 (NCT 03610802) Title: Send-In Sample Collection to Achieve Genetic and Immunologic Characterization of Primary Immunodeficiencies
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
This manuscript will be submitted for peer-review and metadata will be included in this submission.
